ACET — Adicet Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1720580 ·
Last close
$8.90
Market Cap
$83.32M
52W High
$9.84
52W Low
$7.02
ADV30
87,241
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -22,301,000 | -21,358,000 | 148,166,000 | 33,131,000 | 28,028,000 |
| Mar 2026 | 0 | — | -21,570,000 | -20,244,000 | 169,382,000 | 36,245,000 | 29,317,000 |
| Dec 2025 | 0 | — | -31,886,000 | -30,516,000 | 192,355,000 | 38,918,000 | 33,145,000 |
| Sep 2025 | 0 | — | -27,952,000 | -26,856,000 | 140,479,000 | 29,099,000 | 31,337,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-84,529,000
Investing CF
$7,831,000
Financing CF
$75,075,000
CapEx
$-495,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-11.45
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-656,299,000
Inventory
—
Receivables
$439,000
ST Investments
$85,059,000
EBIT TTM
$-98,750,000
Pretax Income TTM
$-98,831,000
Interest Exp TTM
$81,000
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,114,000 | -116,803,000 | 192,355,000 | 33,145,000 | — | -95,246,000 |
| Dec 2024 | 0 | -127,615,000 | -117,122,000 | 220,219,000 | 33,610,000 | — | -92,378,000 |
| Dec 2023 | 0 | -132,576,000 | -142,658,000 | 207,295,000 | 37,120,000 | — | -93,717,000 |
| Dec 2022 | 24,990,000 | -72,551,000 | -69,790,000 | 330,690,000 | 38,352,000 | — | -44,765,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.95
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc. | $83.66M | $4.87 | — |
| ATHE | ALTERITY THERAPEUTICS LTD | $82.83M | $4.57 | — |
| CING | Cingulate Inc. | $82.60M | $5.68 | — |
| MAIA | MAIA Biotechnology, Inc. | $82.11M | $1.35 | — |
| GOSS | Gossamer Bio, Inc. | $85.55M | $0.17 | — |
News headlines (Yahoo Finance, 1h cache)
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
2026-08-18 13:40 · Yahoo
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy
2026-08-11 16:04 · Yahoo
All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy
2026-08-10 16:00 · Yahoo
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
2026-07-21 20:00 · Yahoo
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
2026-07-01 13:40 · Yahoo
Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology
2026-06-29 01:27 · Yahoo
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference
2026-06-04 18:04 · Yahoo
Here's Why You Should Add ACET Stock to Your Portfolio Now
2026-08-24 14:09 · Yahoo
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet
2026-08-14 13:55 · Yahoo
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-05 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.